IBC Review and Consulting Services

Accomplish Rapid Study Startup for Vaccine and Gene Therapy Trials

Advarra’s diverse roster of career biosafety professionals and proven solutions will help you help you shorten your study startup timelines. While our standard IBC review turnaround time is 10 business days or less, we’ve been able to complete reviews for COVID-19 trials in an average of 4.1 business days.

With years of experience providing comprehensive reviews and oversight of research involving recombinant DNA, synthetic nucleic acid molecules, genetic engineering, and gene therapy research, our experts will help move your research forward. To learn more about our capabilities, check out our detailed IBC info sheet.

Ready for reliable study startup support? Fill out the form to schedule a meeting and get started with Advarra IBC.